コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ., attention deficit hyperactivity disorder, drug addiction).
2 ng abstinence is a defining feature of human drug addiction.
3 tors of neuropsychiatric diseases, including drug addiction.
4 ortant in the development and persistence of drug addiction.
5 ications in reward memory and development of drug addiction.
6 rs such as posttraumatic stress disorder and drug addiction.
7 tosensory system functional development, and drug addiction.
8 biomarkers and novel therapeutic targets for drug addiction.
9 the modulation of mood disorders as well as drug addiction.
10 to advance cannabinoid-based treatments for drug addiction.
11 tric disorders such as Parkinson disease and drug addiction.
12 vention of dysfunctional DA transmission and drug addiction.
13 lso inform the development of treatments for drug addiction.
14 long-term synaptic plasticity, learning, and drug addiction.
15 attention-deficit hyperactivity disorder and drug addiction.
16 investigated in animal and human research on drug addiction.
17 pathophysiology of complex disorders such as drug addiction.
18 s a role in L-dopa-induced dyskinesia and in drug addiction.
19 ch as autism, schizophrenia, Alzheimer's and drug addiction.
20 tensive health complications associated with drug addiction.
21 lie several psychiatric disorders, including drug addiction.
22 including maladaptive responses involved in drug addiction.
23 havioral processes related to motivation and drug addiction.
24 ar mechanisms controlling mood disorders and drug addiction.
25 is circuit might alter behaviours related to drug addiction.
26 ny diseases and psychopathologies, including drug addiction.
27 behavioral and neurobiological framework as drug addiction.
28 nt of astrocytes in human pathophysiology of drug addiction.
29 target toward treating pain, depression, and drug addiction.
30 rovide new insights into the neurobiology of drug addiction.
31 buse is hypothesized to increase the risk of drug addiction.
32 sting OX1 antagonism could be therapeutic in drug addiction.
33 iological processes including locomotion and drug addiction.
34 ent and relapse of drug-seeking behaviors in drug addiction.
35 prevention and treatment of both obesity and drug addiction.
36 vulnerability to relapse in rodent models of drug addiction.
37 provide promising therapeutic approaches in drug addiction.
38 ders including schizophrenia, depression and drug addiction.
39 such disorders as impulsivity, obesity, and drug addiction.
40 umans, paralleling the tolerance observed in drug addiction.
41 g neurocognitive endophenotype for stimulant drug addiction.
42 itivity, a known risk factor for alcohol and drug addiction.
43 rizes disorders ranging from binge eating to drug addiction.
44 ately identify new treatments for obesity or drug addiction.
45 l area (VTA) are involved at early phases of drug addiction.
46 s for epigenetic therapeutics in alcohol and drug addiction.
47 Immunotherapy is a promising treatment for drug addiction.
48 Hypocretin (orexin) signaling is involved in drug addiction.
49 aviors in the development of opioid-mediated drug addiction.
50 pioids, a potentially important mechanism in drug addiction.
51 contingent punishment is a core phenotype of drug addiction.
52 naptic plasticity, associative learning, and drug addiction.
53 ons into the epigenetic and genetic basis of drug addiction.
54 ophrenia, obsessive-compulsive disorder, and drug addiction.
55 echanisms may therefore underlie obesity and drug addiction.
56 een suggested, but never directly tested, in drug addiction.
57 ex (ACC) have been implicated in alcohol and drug addiction.
58 mate behaviors spanning anxiety behavior and drug addiction.
59 tex (ACC) has been implicated in alcohol and drug addiction.
60 rd-based conditioning and the development of drug addiction.
61 g cognitive demand are a hallmark deficit in drug addiction.
62 ) neurons underlies a key pathophysiology of drug addiction.
63 tagonism as a potential treatment option for drug addiction.
64 e extensive knowledge of the neurobiology of drug addiction.
65 disorders such as post-traumatic stress and drug addiction.
66 is a key component of the pathophysiology of drug addiction.
67 a role for orexins in reward processing and drug addiction.
68 psychiatric disorders, including anxiety and drug addiction.
69 r example post-traumatic stress disorder and drug addiction.
70 ehavioral and pharmacological treatments for drug addiction.
71 administration environment are important in drug addiction.
72 may regulate plasticity processes underlying drug addiction.
73 erbate neuropsychiatric disorders, including drug addiction.
74 king habits that are a key characteristic of drug addiction.
75 anisms mediating adolescent vulnerability to drug addiction.
76 ts into the genesis and neural mechanisms of drug addiction.
77 urrently being evaluated in animal models of drug addiction.
78 ea, a region required for the development of drug addiction.
79 uding plasticity, nociception, epilepsy, and drug addiction.
80 tropic glutamate receptors in alcoholism and drug addiction.
81 ay critical roles in synaptic plasticity and drug addiction.
82 oup I mGluRs in reward-related behaviors and drug addiction.
83 bit is a major challenge to the treatment of drug addiction.
84 itical to the development and persistence of drug addiction.
85 disorders including Parkinson's disease and drug addiction.
86 recently, for unconventional targets such as drug addiction.
87 ladaptive decision-making that characterizes drug addiction.
88 s to maximize pharmacological treatments for drug addiction.
89 ic strategy for the prevention of relapse in drug addiction.
90 lay a central role in reward, motivation and drug addiction.
91 a formidable challenge for the treatment of drug addiction.
92 behavioral sensitization, an animal model of drug addiction.
93 ys an important role in the etiology of this drug addiction.
94 arkinson's disease, Alzheimer's disease, and drug addiction.
95 been hypothesized to drive the transition to drug addiction.
96 linical treatment of chronic pain and opioid drug addiction.
97 d in Parkinson's disease, schizophrenia, and drug addiction.
98 ioral choice and may be a critical factor in drug addiction.
99 interventions could be effective in treating drug addiction.
100 to impaired impulse control associated with drug addiction.
101 al striatum (VS) as a possible treatment for drug addiction.
102 vel and effective therapeutic strategies for drug addiction.
103 nalling in the brain plays a central role in drug addiction.
104 entral to the development and maintenance of drug addiction.
105 iated with compulsive obsessive disorder and drug addiction.
106 animals toward risky options and facilitate drug addiction.
107 athological conditions, such as gambling and drug addiction.
108 include generalized anxiety, depression, and drug addiction.
109 Ca2 channels (KCNN1-3) influence alcohol and drug addiction.
110 t process for candidate medications to treat drug addiction.
111 regions of genes that have pivotal roles in drug addiction.
112 underpinnings for compulsive overeating and drug addiction.
113 numerous societal problems, from obesity to drug addiction.
114 , RPE signaling is thought to be impaired in drug addiction.
115 relapses that are common in adolescent-onset drug addiction.
116 implicated in neurodegenerative disease and drug addiction.
117 lasticity, which is involved in learning and drug addiction.
118 as posttraumatic stress disorder (PTSD) and drug addiction.
119 implicated in neurodegenerative disease and drug addiction.
120 been associated with different dimensions of drug addiction.
121 new therapeutic avenue for the treatment of drug addiction.
122 pulsivity as key psychological constructs in drug addiction.
123 the pharmacogenetic treatment of alcohol and drug addiction.
124 europsychiatric disorders including PTSD and drug addiction.
125 reward processing and motivated behavior in drug addiction.
126 fy the efficacy of maintenance treatments in drug addiction.
127 not been explicitly tested in the context of drug addiction.
128 ting other neurological disorders, including drug addiction.
129 nduced drug relapse, a major factor in human drug addiction.
130 stress reactivity are central components in drug addiction.
131 se in treating neuropsychiatric diseases and drug addictions.
132 ent with observations in human subjects with drug addictions.
133 ; AOR, 1.96 [95% CI, 1.16-3.30]); history of drug addiction (4.5% stillbirths, 2.1% live births) (vs
134 ent (beta-estimate = 17.9; P = 0.004) and of drug addiction absence (beta estimate = 14.6; P = 0.049)
136 of reward neural circuitry, but I argue that drug addiction also involves another major source of rei
137 the enormous societal burden of alcohol and drug addiction and abundant research describing drug-ind
142 pation and dysregulation of these systems in drug addiction and evaluates the current understanding o
143 itical to the acquisition and maintenance of drug addiction and is modulated strongly by nicotine act
153 and their potential therapeutic benefits in drug addiction and other neuropsychiatric changes in rew
154 been considered as potential medications for drug addiction and other neuropsychiatric disorders.
155 motional/motivational alterations related to drug addiction and other psychiatric disorders, and thes
157 studied for its association in a variety of drug addiction and pain sensitivity phenotypes; however,
161 l area (VTA) is a brain region implicated in drug addiction and related behaviors; however, little re
165 Since epigenetic changes are implicated in drug addiction and tolerance phenomenon, this study coul
167 evelopment of pharmacological treatments for drug addiction and, more generally, further our understa
168 reported among individuals with alcohol and drug addictions and contribute to the acquisition and ma
170 one of the primary behavioral components of drug addiction, and cue-elicited craving is an especiall
171 abuse or stress mediates certain aspects of drug addiction, and depressive and anxiety-like behavior
172 rst time this impaired insight hypothesis in drug addiction, and examined its potential association w
173 would someday lead to better treatments for drug addiction, and he would be gratified to know that s
174 mily of KCNN genes in alcohol, nicotine, and drug addiction, and identify KCNN3 as a mediator of volu
175 viors, including cognition, pain perception, drug addiction, and memory consolidation, and they have
178 role in the motivational systems underlying drug addiction, and recent work has suggested that they
179 ranging from depression to eating disorders, drug addiction, and related compulsive pursuits of rewar
181 of plasticity that control vulnerability to drug addiction, and that this increased vulnerability is
182 triatal function in models of depression and drug addiction, and thus we hypothesized that dorsal str
183 d to the compulsive behavior associated with drug addiction, and which are non-specific changes relat
185 licated in several disease states, including drug addiction, anxiety, depression, obesity, and chroni
188 ment of neuropsychiatric disorders including drug addiction, as well as prefrontal cortical refinemen
189 een postulated as a behavioral treatment for drug addiction based on its preventive effects in animal
190 cal gamblers in core circuitry implicated in drug addiction, but also highlights some subtle differen
193 y induced by drugs of abuse for behaviors of drug addiction, but GluA1 roles in emotional learning an
194 retin/orexin system plays a critical role in drug addiction, but the potential participation of this
196 the possibility of developing therapies for drug addiction by targeting ASIC-dependent neurotransmis
200 ransition from casual drug use to compulsive drug addiction could aid in the development of treatment
201 physiology of several human diseases such as drug addiction, depression, neurodegenerative disorders,
204 chanisms that underlie the predisposition to drug addiction from effects of drugs in adolescents.
208 These observations echo two core features of drug addiction: high motivation to seek addictive substa
209 striatum is important for the development of drug addiction; however, a precise understanding of the
210 h as obsessive-compulsive disorder (OCD) and drug addiction; however, additional work is needed to ad
211 tion of the brain's reward circuitry seen in drug addiction; however, the specific genes regulated an
216 M1 have been implicated in predisposition to drug addiction, in particular the single nucleotide poly
219 ined in areas of the mouse brain involved in drug addiction, including the ventral tegmental area (VT
241 s addicted, but the likelihood of developing drug addiction is greater in people with a family histor
243 ggest treating the stress-related aspects of drug addiction is likely to be an important contributing
248 Importance: A common trigger for relapse in drug addiction is the experience of craving via exposure
254 in NAc function similar to those underlying drug addiction may contribute to obesity, particularly i
255 merging evidence suggesting that obesity and drug addiction may share common hedonic mechanisms will
256 r interactions between circadian rhythms and drug addiction, mechanisms for such interactions remain
257 in midbrain dopaminergic regions involved in drug addiction, mental illness, and movement control in
259 using the theoretical framework of prominent drug addiction models, investigating the neurobiological
260 itters in the control of energy homeostasis, drug addiction, mood and motivation, sleep-wake states,
261 ate in sleep regulation, energy homeostasis, drug addiction, motor regulation, stress response, and s
262 mine D2 receptor (D2R) and are implicated in drug addiction, movement disorders, and nociception.
264 nd its activator p35 have been implicated in drug addiction, neurodegenerative diseases such as Alzhe
265 s implicated in various mental disorders and drug addiction, no studies have explored the impact of e
266 d role of glutamatergic neurotransmission in drug addiction, novel medication development strategies
268 ders of the CNS, including schizophrenia and drug addiction, our findings have substantial clinical r
269 s been widely studied for its association in drug addiction, pain sensitivity, and, more recently, so
273 susceptibility to a complex disorder such as drug addiction provides a foundation for clinical associ
274 t not those to BRAFi alone, displayed robust drug addiction, providing a potentially exploitable ther
277 g opiate methadone is commonly used to treat drug addiction, relatively little is known about the eff
281 nderstanding of the neurobiological basis of drug addiction requires examination of real-time (subsec
284 myriad neuropsychiatric disorders, including drug addiction, schizophrenia, depression, epilepsy, and
286 s been the understanding that the process of drug addiction shares striking commonalities with neural
287 jections, are often used as a model to study drug addiction, similar effects have been difficult to d
289 addictions share many clinical features with drug addictions, they show strikingly large variation in
290 he future treatment of relapse prevention in drug addiction through memory reconsolidation blockade.
291 Here we used established rodent models of drug addiction to determine whether they would be sensit
294 n is postulated to increase vulnerability to drug addiction-was impaired in both adolescent mice and
296 he striatum is involved in the mechanisms of drug addiction, we studied how the transgene affected st
297 Abnormal alteration of spines may occur in drug addiction when opioid receptors are overactivated b
299 of the hormonal and brain stress systems in drug addiction with a focus on the changes that occur du
300 postulated to play key roles in alcohol and drug addiction; yet, to date, little is understood regar
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。